COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Temas Opens New RCL Metallurgical Lab to Accelerate Technology Deployment and Third-Party Revenue Opportunities
Temas Resources Corp. establishes Technology Research and Development Centre metallurgical lab in Ontario, Canada, to support RCL technology scale-up, third-party contracts, and global licensing opportunities. The lab will enhance process optimization, pilot-scale testing, and facilitate exploration and third-party material testwork -
COMMUNIQUÉ DE PRESSE
Neural Cloud Signs Reseller Agreement with European Digital Cardiac Monitoring Platform
AI/ML Innovations Inc. announces collaboration with European digital health platform to integrate MaxYield™ ECG signal-processing technology for remote cardiac monitoring solutions, expanding access to advanced ECG signal analysis for healthcare providers -
COMMUNIQUÉ DE PRESSE
Galway Metals Intersects Thick Gold-Antimony Mineralization at South Deposit, Including 6.1 g/t Au and 0.7% Sb Over 28.0m
Galway Metals reports high-grade gold and antimony mineralization at Clarence Stream project in New Brunswick, Canada. The drilling program shows promising results -
-
COMMUNIQUÉ DE PRESSE
Sun Peak Metals Awarded 100% Ownership of Seven New Exploration Licenses Totaling 632 km2 in Saudi Arabia
Sun Peak Metals Corp. acquires seven exploration licenses totaling 632 km² in Saudi Arabia's Round 9 auction, expanding its footprint on highly prospective ground for VMS and gold mineralization -
-
COMMUNIQUÉ DE PRESSE
ATHA Energy Initiates Ongoing Site Mobilization in Advance Of 2026 Angilak Exploration Program - Exploration Activities Commencing in April
ATHA Energy Corp. announces the commencement of the 2026 Angilak mobilization for its exploration program at the Angilak Uranium Project in Nunavut, fully funded with CAD $63 Million financing. Exploration activities expected to start in April -
COMMUNIQUÉ DE PRESSE
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
Immunic strengthens its Board of Directors with the appointment of seasoned biopharmaceutical executive Jon Congleton on March 31, 2026, to support the development of novel oral therapies for neurologic diseases -
